The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model

Inflammation Research

Volumn 61, Issue 11, 2012, Pages 1211-1218

  Jeong, Su Jin ^a   Lim, Beom Jin ^a   Park, Sungha ^a   Choi, Donghoon ^a   Kim, Hye Won ^a   Ku, Nam Su ^a   Han, Sang Hoon ^a   Kim, Chang Oh ^a   Choi, Jun Yong ^a   Song, Young Goo ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cecal ligation and puncture; Cytokine; Mortality; Severe sepsis; sRAGE Fc fusion protein

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCT IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; INFECTION PREVENTION; LIGATION; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUNCTURE; SEPSIS; SURVIVAL; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CECUM; CYTOKINES; DISEASE MODELS, ANIMAL; LIGATION; MICE; MICE, INBRED C57BL; PNEUMONIA; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SEPSIS;

EID: 84868138835     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0518-7     Document Type: Article

References (35)

1. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med. 2005;56:225-8.
2. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med. 2003;138:502-5.
3. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-5004.
4. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-97.
5. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270:25752-61.
6. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
7. Chavakis T, Bierhaus A, Al Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507-15.
8. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002;105:816-22.
9. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997;272:16498-506.
10. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-4.
11. Schmidt AM, Yan SD, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Investig. 2001;108:949-55.
12. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656-66.
13. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grne H, Kurschus FC, Schmidt AM, Du Yan S, Martin E, Schleicher E, Stern DM, Hämmerling GG, Nawroth P, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Investig. 2004;113:1641-50.
14. Lutterloh EC, Opal SM, Pittman D, Keith JC, Tan X, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007;11:R122-R.
15. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21:75-87.
16. Rittirsch D, HuberLang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protocol. 2009;4:31-6.
17. Oliveira GP, Oliveira MB, Santos RS, Lima LD, Dias CM, Ab' Saber AM, Teodoro WR, Capelozzi VL, Gomes RN, Bozza PT, Pelosi P, Rocco PR. Intravenous glutamine decreases lung and distal organ injury in an experimental model of abdominal sepsis. Crit Care. 2009;13:R74.
18. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005;4:854-65.
19. Orfanos SE, Mavrommati I, Korovesi I, Roussos C. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med. 2004;30:1702-14.
20. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;274:19919-24.
21. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Hring HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50:2792-808.
22. Zen K, Chen CX, Chen Y, Wilton R, Liu Y. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol. 2007;178:2483-90.
23. Rasaiah VP, Malloy JL, Lewis JF, Veldhuizen RA. Early surfactant administration protects against lung dysfunction in a mouse model of ARDS. Am J Physiol. Lung Cell Mol Physiol. 2003;284:L783-L90.
24. Slutsky AS, Tremblay LN. Multiple system organ failure. Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med. 1998;157:1721-5.
25. van Zoelen MA, Schouten M, de Vos AF, Florquin S, Meijers JC, Nawroth P, Bierhaus A, van der Poll T. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol. 2009;182:4349-56.
26. van Zoelen MA, Schmidt A, Florquin S, Meijers JC, de Beer R, de Vos AF, Nawroth P, Bierhaus A, van der Poll T. Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis. 2009;200:765-73.
27. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 2005;11:892-8.
28. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2009;284:8217-21.
29. Kang N, Yoon H, Lee Y, Won M, Chung MJ, Park J, Hur GM, Lee H, Park B. A20 attenuates allergic airway inflammation in mice. J Immunol. 2009;183:1488-95.
30. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth P, Martin E, Weigand MA. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care. 2008;12:201.
31. Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol. 2004;24:4880-94.
32. van Zoelen MA, van der Poll T. Targeting RAGE in sepsis. Crit Care. 2008;12:103.
33. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950-4.
34. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170:1310-6.
35. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, Seki H, Ogawa Y, Miyamoto K, Nakano Y, Hasegawa N, Miyasho T, Maruyama I, Ishizaka A. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med. 2008;178:356-62.